IMMIX BIOPHARMA INC.
1.6000
05-十一月-24 14:59:59
15 分钟延时
股票
+0.0200
+1.27%
今日范围
1.4800 - 1.6000
ISIN
N/A
来源
NASDAQ
-
02 10月 2024 08:32:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
28 8月 2024 08:32:00 条件 Nasdaq GlobeNewswire
-
25 7月 2024 20:31:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
08 7月 2024 08:31:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
17 6月 2024 08:35:00 条件 Nasdaq GlobeNewswire
-
10 5月 2024 08:35:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 4月 2024 08:39:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 4月 2024 08:32:00 条件 Nasdaq GlobeNewswire
-
20 3月 2024 08:46:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 3月 2024 08:35:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma 12 Month Review Progress Update
21 2月 2024 08:31:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 2月 2024 15:45:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 2月 2024 08:37:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 2月 2024 21:30:00 条件 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 2月 2024 14:20:11 条件 Nasdaq GlobeNewswire
-
24 1月 2024 07:35:00 条件 Nasdaq GlobeNewswire
-
18 12月 2023 08:39:00 条件 Nasdaq GlobeNewswire
- <<
- <
- 1
- >